C C177536 GDC Property Terminology C177618 Sequencing Library Read Strategy A method or strategy used for sequencing and analysis of reads from a nucleotide library. library_strategy library strategy C C177536 GDC Property Terminology C177549 Intergroup Rhabdomyosarcoma Study Clinical Grouping System A system developed by the Intergroup Rhabdomyosarcoma Studies (IRS) group for categorizing rhabdomyosarcoma patients in treatment groups based on whether a surgeon can remove the tumor. irs_group irs group C C177536 GDC Property Terminology C177550 Intergroup Rhabdomyosarcoma Study Clinical Staging System A system developed by the Intergroup Rhabdomyosarcoma Studies (IRS) group for staging rhabdomyosarcomas based on a modified TNM staging system. irs_stage irs stage A C177537 GDC Value Terminology C152714 Transferrin Aldifitox A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. (NCI04) Transferrin-CRM107 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C169863 Conteltinib An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, conteltinib selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis. ALK/FAK/Pyk2 Inhibitor CT-707 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C175756 Cirtuvivint An orally bioavailable small molecule ATP-competitive inhibitor of CDC2-like kinase (CLK) and dual specificity tyrosine-phosphorylation-regulated kinase (DYRK) family kinases, with potential antineoplastic activity. Upon oral administration, cirtuvivint targets, binds to and inhibits the activity of CLK and DYRK family of protein kinases, including CLK1-4 and DYRK1-4, thereby inhibiting the phosphorylation of serine/arginine-rich (SR) domain-containing splicing factors (SFs). This modulates RNA splicing and inhibits the expression of genes involved in the Wnt signaling pathway. This decreased expression of Wnt pathway-related genes prevents Wnt signaling and may inhibit proliferation of cancer cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is dysregulated in many cancer cell types and plays a crucial role in tumor cell proliferation. CLK and DYRK family kinases, evolutionarily conserved groups of dual specificity kinases, phosphorylate various SR proteins including SR domain-containing SFs. Wnt Signaling Pathway Inhibitor SM08502 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C184838 Edaxeterkib An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, edaxeterkib specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells. ERK1/2 Inhibitor KO-947 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C190593 Malignant Liver Neoplasm A primary or metastatic malignant neoplasm that affects the liver. Liver Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis A C177537 GDC Value Terminology C199125 Vabametkib An orally bioavailable, highly selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, vabametkib targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. c-Met Inhibitor ABN401 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C199130 Vonsetamig A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, vonsetamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C203062 Volamcabtagene Durzigedleucel A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, volamcabtagene durzigedleucel recognizes and binds to CD70-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host disease (GvHD); the disruption of MHC class I molecules increases the persistence of the CAR T-cells. Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C211698 Lasmecabtagene Timgedleucel A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, lasmecabtagene timgedleucel bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells. Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C211709 Zabilugene Almadenorepvec An oncolytic, replication-competent adenovirus encoding the human glycosylphosphatidylinositol-anchored enzyme PH20 hyaluronidase with potential antitumor activity. After intratumoral administration, zabilugene almadenorepvec selectively replicates in tumor cells, which may both cause oncolytic virus-induced cell death and induce the infection of adjacent tumor cells. In addition, the virus expresses hyaluronidase, which hydrolyzes and degrades the hyaluronic acid (HA) that coats tumor cells. The degradation of HA may result in a decrease for both the viscosity of the interstitial space and the tumor's interstitial fluid pressure (IFP). This increases viral spread and may result in the inhibition of tumor cell growth. In addition, HA degradation facilitates the penetration of chemotherapeutic agents into the tumor. HA is a glycosaminoglycan found in the extracellular matrix (ECM) and is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increases in tumor cell growth, metastatic potential, tumor progression and resistance to chemotherapeutic agents. PH20 Hyaluronidase-expressing Adenovirus VCN-01 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C214799 Myomatous Neoplasm A benign, intermediate, or malignant mesenchymal neoplasm that arises from smooth, skeletal, or cardiac muscle cells. Myomatous Neoplasms | disease_type C2991 disease_type A C177537 GDC Value Terminology C214801 Myosarcoma An aggressive mesenchymal neoplasm with malignant histopathological features that arises from smooth, skeletal, or cardiac muscle cells. This category includes leiomyosarcomas and rhabdomyosarcomas. 8895/3 | morphology || Myosarcoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C215289 Anzutresgene Autoleucel A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, anzutresgene autoleucel specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types. Autologous TCR-engineered T-cells IMA203 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C223358 Pancreaticobiliary Mucinous Cystic Neoplasm, High Grade A non-invasive neoplasm that arises from the exocrine pancreas, gallbladder, or bile ducts and is characterized by the presence of neoplastic columnar mucin-producing epithelial cells that form papillae with irregular branching and budding, cystic changes, underlying ovarian-type stroma, and severe dysplasia. Mitotic activity is present and the mitoses may be atypical. 8163/2 | morphology || 8470/2 | morphology || Mucinous cystic neoplasm with high-grade dysplasia | primary_diagnosis || Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia | primary_diagnosis || Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia | primary_diagnosis || Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C223377 Pancreaticobiliary Mucinous Cystic Neoplasm, Low Grade A non-invasive neoplasm that arises from the exocrine pancreas, gallbladder, or bile ducts and is characterized by the presence of neoplastic columnar mucin-producing epithelial cells that form papillae, cystic changes, underlying ovarian-type stroma, and mild dysplasia. 8163/0 | morphology || Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia | primary_diagnosis || Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C223378 Pancreaticobiliary Mucinous Cystic Neoplasm A non-invasive neoplasm that arises from the exocrine pancreas, gallbladder, or bile ducts and is characterized by the presence of neoplastic columnar mucin-producing epithelial cells that form papillae, cystic changes, underlying ovarian-type stroma, and dysplasia. It is classified as low- or high-grade. 8163/0 | morphology || Pancreatobiliary neoplasm, non-invasive | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C223514 Pancreaticobiliary Intraductal Tubulopapillary Neoplasm A non-invasive epithelial neoplasm that arises from the exocrine pancreas and bile ducts and is characterized by ductal differentiation, formation of tubular structures, presence of nodules and occasional papillary structures in dilated ducts, high grade dysplasia, and absence of significant mucin production. Intraductal tubulopapillary neoplasm | primary_diagnosis C177621 primary_diagnosis A C177537 GDC Value Terminology C227650 Malignant Bile Duct Neoplasm A primary or metastatic malignant neoplasm that affects the intrahepatic bile ducts, hepatic ducts, common bile duct, or cystic duct. Bile Duct Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis A C177537 GDC Value Terminology C40076 Ovarian Clear Cell Tumor A benign, borderline, or malignant epithelial tumor of the ovary that is characterized by a predominance of clear and hobnail cells. 8005/0 | morphology || Clear cell tumor, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C5201 Breast Intraductal Papillomatosis A benign breast neoplasm characterized by the presence of multiple intraductal papillomas. Diffuse intraductal papillomatosis | primary_diagnosis C177621 primary_diagnosis A C177537 GDC Value Terminology C6192 Inverted Urothelial Papilloma An endophytic urothelial neoplasm arising from the urinary tract. It shares several morphologic features with urothelial papilloma. 8121/0 | morphology || 8121/1 | morphology || Transitional cell papilloma, inverted, NOS | primary_diagnosis || Transitional cell papilloma, inverted, benign | primary_diagnosis || Transitional papilloma, inverted, NOS | primary_diagnosis || Transitional papilloma, inverted, benign | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C6510 Leiomyoma A well-circumscribed benign neoplasm that arises from smooth muscle cells and is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. 8890/0 | morphology || Leiomyoma | additional_pathology_findings || Leiomyoma, NOS | primary_diagnosis C158809 || C176985 || C177621 additional_pathology_findings || morphology || primary_diagnosis A C177537 GDC Value Terminology C7153 Differentiated Thyroid Gland Carcinoma An adenocarcinoma that arises from the thyroid gland and shows extensive evidence of follicular cell differentiation. According to the nuclear features of the malignant follicular cells, it is classified either as papillary or follicular carcinoma. 8340/3 | morphology || Papillary and follicular adenocarcinoma | primary_diagnosis || Papillary and follicular carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C7287 Ovarian Granulosa-Stromal Cell Tumor A group of sex cord-stromal tumors that arise from the ovary. These tumors are characterized by the presence of granulosa cells, stromal cells, and/or theca cells. This group includes granulosa cell tumor and tumors of the thecoma/fibroma group. 8621/1 | morphology || Granulosa cell-theca cell tumor | primary_diagnosis || Theca cell-granulosa cell tumor | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C7347 Cervical Squamous Intraepithelial Neoplasia 3 Cervical squamous intraepithelial neoplasia characterized by the presence of nuclear atypia and mitotic figures throughout the entire thickness of the squamous epithelium, and maturation that is absent or confined to the upper third of the epithelium. 8077/2 | morphology || CIN III with severe dysplasia | primary_diagnosis || Cervical intraepithelial neoplasia, grade III | primary_diagnosis || Cin III, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C7481 Malignant Gallbladder Neoplasm A primary or metastatic malignant neoplasm that affects the gallbladder. Gallbladder Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis C C177537 GDC Value Terminology C102855 Lapiteronel An orally bioavailable, non-steroidal, potent, reversible, dual inhibitor of cytochrome P450 17 (CYP17 or CYP17A1) and CYP11B2, with potential antiandrogen and antineoplastic activities. Upon oral administration, lapiteronel inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. Lapiteronel also inhibits the enzymatic activity of CYP11B2, thereby inhibiting aldosterone production. This may reduce the elevated aldosterone levels resulting from CYP17 inhibition and androgen deprivation, leading to a reduction in mineralocorticoid side effects including cardiovascular complications. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. The cytochrome P450 enzyme CYP11B2, aldosterone synthase, is an enzyme that plays a key role in aldosterone biosynthesis. CYP17 Inhibitor CFG920 | therapeutic_agents || CYP17/CYP11B2 Inhibitor LAE001 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C102980 Anti-ENPP3 Antibody-drug Conjugate AGS-16C3F An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms. Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C1062 Daunorubicinol An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicinol exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04) Duborimycin | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C106266 Anti-CD27L Antibody-drug Conjugate AMG 172 An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types. Anti-CD27L Antibody-Drug Conjugate AMG 172 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C107388 Anti-5T4 Antibody-drug Conjugate PF-06263507 An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness. Anti-5T4 Antibody-Drug Conjugate PF-06263507 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C113293 Supinoxin An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, supinoxin may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence. P-p68 Inhibitor RX-5902 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C116066 Surufatinib An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, surufatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types. Sulfatinib | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C116626 Anti-ENPP3/MMAF Antibody-drug Conjugate AGS-16M8F An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers. Anti-ENPP3/MMAF Antibody-Drug Conjugate AGS-16M8F | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C116742 Anti-ETBR/MMAE Antibody-drug Conjugate DEDN6526A An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis. Anti-ETBR/MMAE Antibody-Drug Conjugate DEDN6526A | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C116746 Anti-mesothelin/MMAE Antibody-drug Conjugate DMOT4039A An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue. Anti-mesothelin/MMAE Antibody-Drug Conjugate DMOT4039A | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C118569 Anti-Notch3 Antibody-drug Conjugate PF-06650808 An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the neurogenic locus notch homolog protein 3 (Notch3) receptor conjugated to an auristatin-based cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-Notch3 ADC PF-06650808, the antibody moiety targets and binds to Notch3 expressed on tumor cells. Upon binding and internalization, the auristatin-based cytotoxic agent binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis of Notch3-expressing tumor cells. Notch3 is overexpressed on a variety of cancer cells. Notch Signaling Inhibitor PF-06650808 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C118572 Anti-EFNA4/Calicheamicin Antibody-drug Conjugate PF-06647263 An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against Ephrin-A4 (EFNA4), conjugated, via a hydrazone-based cleavable linker, to the DNA damaging agent calicheamicin, with potential antineoplastic activity. Upon administration of anti-EFNA4/calicheamicin ADC PF-06647263, the anti-EFNA4 monoclonal antibody moiety targets and binds to EFNA4 expressed on tumor cells. Upon binding, internalization and linker cleavage, calicheamicin is released and binds to the minor groove of DNA, causing double strand DNA breaks and may result in the inhibition of DNA synthesis and cell death in EFNA4-expressing tumor cells. EFNA4 is overexpressed by a variety of different cancer cell types and its expression is correlated with increased proliferation, invasion, and metastasis. Antibody-drug Conjugate PF-06647263 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C119618 HIF-2alpha Inhibitor MK-3795 An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor MK-3795 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancers, promotes tumorigenesis. HIF-2alpha Inhibitor PT2385 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C120312 Imofinostat An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon administration, imofinostat selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in both an induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. This prevents cell division and induces both cell cycle arrest and apoptosis, which may inhibit the proliferation of susceptible tumor cells. In addition, imofinostat inhibits the phosphorylation and activation of Akt, which prevents the activation of downstream signaling pathways, independent of its HDAC inhibitory activity. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins. Akt, overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and survival. HDAC Inhibitor MPT0E028 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C12360 Abdominal Lymph Node Any lymph node within the abdomen. Intra-Abdominal, NOS | lymph_node_involved_site || Intra-abdominal lymph nodes | progression_or_recurrence_anatomic_site || Intra-abdominal lymph nodes | site_of_resection_or_biopsy || Intra-abdominal lymph nodes | tissue_or_organ_of_origin C156421 || C156422 || C177570 || C198127 lymph_node_dissection_site || progression_or_recurrence_anatomic_site || site_of_resection_or_biopsy || tissue_or_organ_of_origin C C177537 GDC Value Terminology C132023 Olafertinib An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, olafertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, olafertinib may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGFR Mutant-specific Inhibitor CK-101 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C133818 Anti-AG7 Antibody-drug Conjugate AbGn-107 An antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells. Anti-AG7 Antibody Drug Conjugate AbGn-107 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C146627 Oral Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips. Oral Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146629 Ventricular Arrhythmia, CTCAE A disorder characterized by a dysrhythmia that originates in the ventricles. Ventricular Arrhythmia | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146631 Rectal Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the rectal region. Rectal Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146633 Ileal Perforation, CTCAE A disorder characterized by a rupture in the ileal wall. Ileal Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146634 Rectal Perforation, CTCAE A disorder characterized by a rupture in the rectal wall. Rectal Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146635 Small Intestinal Perforation, CTCAE A disorder characterized by a rupture in the small intestine wall. Small Intestinal Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146637 Gastrointestinal Fistula, CTCAE A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site. Gastrointestinal Fistula | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146642 Serum Sickness, CTCAE A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea. Serum Sickness | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146645 Precocious Puberty, CTCAE A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys. Precocious Puberty | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146663 Pleuritic Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the pleura. Pleuritic Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146664 Prostatic Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the prostate gland. Prostatic Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146665 Scrotal Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the scrotal area. Scrotal Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146666 Testicular Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the testis. Testicular Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146674 Cataract, CTCAE A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated. Cataract | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146677 Vitreous Hemorrhage, CTCAE A disorder characterized by bleeding into the vitreous humor. Vitreous Hemorrhage | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146679 Pelvic Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the pelvis. Pelvic Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146680 Penile Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the penis. Penile Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146681 Perineal Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus. Perineal Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146682 Phantom Pain, CTCAE A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body. Phantom Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146683 Uterine Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the uterus. Uterine Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146684 Vaginal Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the vagina. Vaginal Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146685 Gynecomastia, CTCAE A disorder characterized by excessive development of the breasts in males. Gynecomastia | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146687 Vaginal Dryness, CTCAE A disorder characterized by an uncomfortable feeling of itching and burning in the vagina. Vaginal Dryness | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146690 Tinnitus, CTCAE A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking. Tinnitus | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146694 Stomal Ulcer, CTCAE A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure. Stomal Ulcer | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146695 Myocarditis, CTCAE A disorder characterized by inflammation of the muscle tissue of the heart. Myocarditis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146696 Vaginal Obstruction, CTCAE A disorder characterized by blockage of vaginal canal. Vaginal Obstruction | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146697 Vaginal Perforation, CTCAE A disorder characterized by a rupture in the vaginal wall. Vaginal Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146698 Bladder Spasm, CTCAE A disorder characterized by a sudden and involuntary contraction of the bladder wall. Bladder Spasm | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146699 Encephalopathy, CTCAE A disorder characterized by a pathologic process involving the brain. Encephalopathy | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146707 Bladder Perforation, CTCAE A disorder characterized by a rupture in the bladder wall. Bladder Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146708 Gallbladder Perforation, CTCAE A disorder characterized by a rupture in the gallbladder wall. Gallbladder Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146714 Fallopian Tube Perforation, CTCAE A disorder characterized by a rupture of the fallopian tube wall. Fallopian Tube Perforation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146729 Retinal Detachment, CTCAE A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium. Retinal Detachment | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146730 Typhlitis, CTCAE A disorder characterized by necrotizing enterocolitis in neutropenic patients. Also referred to as neutropenic enterocolitis, ileocecal syndrome, or cecitis. Typhlitis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146731 Asystole, CTCAE A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart. Asystole | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146732 Ventricular Fibrillation, CTCAE A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles. Ventricular Fibrillation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146733 Ventricular Tachycardia, CTCAE A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His. Ventricular Tachycardia | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146735 Gallbladder Necrosis, CTCAE A disorder characterized by a necrotic process occurring in the gallbladder. Gallbladder Necrosis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146736 Hepatic Necrosis, CTCAE A disorder characterized by a necrotic process occurring in the hepatic parenchyma. Hepatic Necrosis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146738 Hemorrhoids, CTCAE A disorder characterized by the presence of dilated veins in the rectum and surrounding area. Hemorrhoids | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146739 Back Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the back region. Back Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146741 Bone Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the bones. Bone Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146742 Breast Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the breast region. Breast Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146743 Chest Wall Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the chest wall. Chest Wall Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146744 Buttock Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the buttocks. Buttock Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146745 External Ear Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the external ear region. External Ear Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146746 Cognitive Disturbance, CTCAE A disorder characterized by a conspicuous change in cognitive function. Cognitive Disturbance | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146747 Dizziness, CTCAE A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking. Dizziness | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146748 Euphoria, CTCAE A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli. Euphoria | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146749 Exostosis, CTCAE A disorder characterized by non-neoplastic overgrowth of bone. Exostosis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146750 Syncope, CTCAE A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain. Syncope | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146751 Eye Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the eye. Eye Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146752 Fallopian Tube Obstruction, CTCAE A disorder characterized by blockage of the normal flow of the contents in the fallopian tube. Fallopian Tube Obstruction | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146753 Fatigue, CTCAE A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities. Fatigue | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146755 Gallbladder Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the gallbladder region. Gallbladder Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146757 Spermatic Cord Obstruction, CTCAE A disorder characterized by blockage of the normal flow of the contents of the spermatic cord. Spermatic Cord Obstruction | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146759 Sinus Tachycardia, CTCAE A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node. Sinus Tachycardia | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146760 Joint Effusion, CTCAE A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation. Joint Effusion | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146761 Lip Pain, CTCAE A disorder characterized by a sensation of marked discomfort of the lip. Lip Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146763 Memory Impairment, CTCAE A disorder characterized by a deterioration in memory function. Memory Impairment | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146766 Neck Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the neck area. Neck Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146767 Osteoporosis, CTCAE A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence. Osteoporosis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146768 Hemoglobinuria, CTCAE A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine. Hemoglobinuria | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146769 Ovulation Pain, CTCAE A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle. Ovulation Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146770 Photophobia, CTCAE A disorder characterized by fear and avoidance of light. Photophobia | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146771 Insomnia, CTCAE A disorder characterized by difficulty in falling asleep and/or remaining asleep. Insomnia | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146772 Scalp Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head. Scalp Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146773 Lymph Node Pain, CTCAE A disorder characterized by a sensation of marked discomfort in a lymph node. Lymph Node Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146774 Stomach Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the stomach. Stomach Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146775 Nystagmus, CTCAE A disorder characterized by involuntary movements of the eyeballs. Nystagmus | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146777 Agitation, CTCAE A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension. Agitation | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146778 Anxiety, CTCAE A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus. Anxiety | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146780 Tremor, CTCAE A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts. Tremor | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146782 Tumor Pain, CTCAE A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis. Tumor Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146783 Sinus Pain, CTCAE A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses. Sinus Pain | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146785 Confusion, CTCAE A disorder characterized by a lack of clear and orderly thought and behavior. Confusion | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146786 Urinary Incontinence, CTCAE A disorder characterized by inability to control the flow of urine from the bladder. Urinary Incontinence | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146787 Myositis, CTCAE A disorder characterized by inflammation involving the skeletal muscles. Myositis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C146788 Cholecystitis, CTCAE A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones. Cholecystitis | adverse_event C41331 adverse_event C C177537 GDC Value Terminology C147031 Anti-MUC16/MMAE Antibody-drug Conjugate DMUC4064A An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation. Anti-MUC16/MMAE Antibody-Drug Conjugate DMUC4064A | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C148066 Bezetabart Debotansine An antibody-drug conjugate (ADC) comprised of bezetabart, an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. Upon administration, the antibody moiety of bezetabart debotansine targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies. Anti-CD74 Antibody-drug Conjugate STRO-001 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C150216 Erenapurstat An orally bioavailable inhibitor of apurinic/apyrimidinic endonuclease 1/reduction-oxidation (redox) effector factor-1 (APE1/Ref-1; APEX1), with potential anti-angiogenic and antineoplastic activities. Upon administration, erenapurstat selectively targets and binds to APE1/Ref-1. This inhibits the redox-dependent signaling activity of APE1/Ref-1, by preventing the reduction and activation of numerous APE1/Ref-1-dependent oncogenic transcription factors (TFs), such as nuclear factor kappa B (NF-kB), AP-1, STAT3, p53, NRF2 and HIF-1alpha, that are involved in signaling, cell proliferation, tumor progression and survival of cancer cells. Therefore, this agent inhibits the activation of multiple TF-mediated signaling pathways and inhibits tumor cell proliferation and survival. APE1/Ref-1, a multifunctional protein overexpressed in many cancer cell types, plays a key role as a redox regulator of transcription factor activation and in base excision repair upon DNA damage. It drives cancer cell proliferation, migration, drug resistance, angiogenesis and inflammation and its expression level correlates with increased tumor aggressiveness and decreased patient survival. Erenapurstat specifically blocks the redox activity of APE1/Ref-1 and does not affect its ability to act as a DNA repair endonuclease. APE1/Ref-1 Redox Inhibitor APX3330 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C150586 Autologous Anti-DLL3 CAR T-Cells AMG 119 A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets the tumor-associated antigen (TAA) delta-like ligand 3 (DLL3), with potential immunomodulatory and antineoplastic activities. Upon administration of the autologous anti-DLL3 CAR T-cells AMG 119, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing DLL3. DLL3, an inhibitory Notch ligand, is expressed on the surface of some cancer cell types but is minimally expressed in normal tissues. CAR T-Cells AMG 119 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C15189 Biopsy Procedure The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. Biopsy | method_of_diagnosis || Biopsy | method_of_sample_procurement C177576 || C70700 method_of_diagnosis || method_of_sample_procurement C C177537 GDC Value Terminology C153427 Gozanertinib An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential antineoplastic activity. Upon oral administration, gozanertinib targets, binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity. EGFR Inhibitor DBPR112 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C156414 Odafosfamide, (R)- The R-isoform of odafosfamide, a small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N'-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, odafosfamide is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, Odafosfamide is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity. AKR1C3-activated Prodrug OBI-3424 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C157575 Anal Intraepithelial Neoplasia III Anal canal or perianal skin intraepithelial neoplasia with severe dysplasia. 8077/2 | morphology || AIN III | primary_diagnosis || Anal intraepithelial neoplasia, grade III | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C1576 Ledoxantrone Trihydrochloride The trihydrochloride salt of the anthrapyrazole antineoplastic antibiotic sedoxantrone with potential antineoplastic activity. Ledoxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Sedoxantrone Trihydrochloride | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C158422 SR Mitomycin Intravesical Solution A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of SR mitomycin intravesical solution , the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in SR mitomycin intravesical solution (UGN-102) the strength of MMC is lower. Sustained-release Mitomycin C Hydrogel Formulation UGN-102 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C162629 Sacubitril Valsartan Sodium Hydrate A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure. Sacubitril/Valsartan | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C164218 Sitneprotafib An orally bioavailable allosteric inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, sitneprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, which are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation. KRAS-MAPK Signaling Pathway Inhibitor JAB-3312 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C16502 Diagnostic Imaging Testing Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. Diagnostic Imaging | method_of_diagnosis C177576 method_of_diagnosis C C177537 GDC Value Terminology C165747 Romaciclib Hydrochloride The hydrochloride salt form of romaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, romaciclib targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation. CDK8/19 Inhibitor SEL 120 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C166377 Plumbagin A synthetic form of the plant-derived medicinal agent, plumbagin, with potential antineoplastic activity. Plumbagin may act by inhibiting the expression of protein kinase C epsilon (PKCe), signal transducers and activators of transcription 3 phosphorylation (Stat3), protein kinase B (AKT), and certain epithelial-to-mesenchymal transition (EMT) markers, including vimentin and slug. This results in possible inhibition of proliferation in susceptible tumor cells. PKCe, Stat3, AKT, and the EMT markers vimentin and slug have been linked to the induction and progression of prostate cancer. Synthetic Plumbagin PCUR-101 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C169105 Amezalpat An orally bioavailable, small molecule, selective and competitive antagonist of peroxisome proliferator activated receptor alpha (PPARa), with potential immunomodulating and antineoplastic activities. Upon oral administration, amezalpat targets, binds to and blocks the activity of PPARa, thereby blocking transcription of PPARa target genes leading to an intracellular metabolism shift from fatty acid oxidation (FAO) to glycolysis in FAO-dependent tumors and reducing the production of fatty acids in the tumor microenvironment (TME). As fatty acids are essential for tumor cell growth in FAO-dependent tumor cells and are needed for the metabolism of suppressive immune cells in the TME, including regulatory T-cells (Tregs), reducing the amount of fatty acids leads to a direct killing of FAO-dependent tumor cells. It also skews macrophages from the immune suppressive M2 phenotype to an effector M1 phenotype and facilitates the cytotoxicity of immune effector cells, thereby stimulating an anti-tumor immune response and further killing tumor cells. Amezalpat also restores the natural inhibitor of angiogenesis thrombospondin-1 (TSP-1) and stimulator of interferon genes (STING) in the TME. PPARa, a ligand-activated nuclear transcription factor and metabolic checkpoint, regulates the expression of FAO genes and lipid metabolism. It plays a key role in immunosuppression in the TME. FAO is a metabolic pathway essential to tumor growth, survival and immunosuppression. PPAR Alpha Antagonist TPST-1120 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C171425 Nuzefatide Pevedotin A bicyclic peptide targeting Ephrin receptor A2 (EphA2) and conjugated, through an inert sarcosine spacer chain and a valine-citrulline cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon administration, nuzefatide pevedotin targets and binds to EphA2-expressing tumor cells. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAE binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types. EphA2 expression is associated with poor prognosis. EphA2-targeting Bicycle Toxin Conjugate BT5528 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C172198 Dulpatatug A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, dulpatatug targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-lymphocyte (CTL) response as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Anti-HER2 Monoclonal Antibody HLX22 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C172639 BAP1-Related Tumor Predisposition Syndrome An autosomal dominant inherited tumor predisposition syndrome caused by germline mutations in the BAP1 gene. Carriers are at an increased risk of developing various neoplasms including BAP1-inactivated melanocytoma, cutaneous melanoma, uveal melanoma, basal cell carcinoma, malignant mesothelioma, and clear cell renal cell carcinoma. BAP1 Tumor Predisposition Syndrome | comorbidities || BAP1 Tumor Predisposition Syndrome | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C172820 Abazistobart A recombinant immunoglobulin G4 (IgG4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, abazistobart targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. Anti-PD-1 Monoclonal Antibody 609A | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C173426 Zedoresertib An orally bioavailable inhibitor of the human tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu), with potential antineoplastic sensitizing activity. Upon oral administration, zedoresertib targets, binds to and inhibits Wee1. Inhibition of Wee1 inhibits Cdk1 (Cdc2) phosphorylation, promotes both premature mitosis and a prolonged mitotic arrest, which results in the accumulation of unrepaired DNA damage. This leads to apoptosis in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, especially in combination with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis. The Wee1 tyrosine kinase is activated upon DNA damage and regulates the G2-M and S cell cycle checkpoints. Wee1 Kinase Inhibitor Debio 0123 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C173983 Ordastobart An agonistic, recombinant, humanized, hexavalent immunoglobulin G (IgG) antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, ordastobart selectively binds to six OX40 receptors per molecule, thereby clustering and activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Utilizing a hexavalent OX40 antibody may improve receptor clustering and downstream signaling over tetravalent or bivalent OX40 antibodies. Anti-OX40 Hexavalent Agonist Antibody INBRX-106 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C175460 Ratangratinib An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3) and colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115; M-CSFR), with potential immunomodulatory and antineoplastic activities. Upon administration, ratangratinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-mediated signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. 3D185 also targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activities of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), and prevents immune suppression in the tumor microenvironment (TME). This enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor that plays major roles in tumor cell proliferation and metastasis. FGFR/CSF-1R Inhibitor 3D185 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C27093 Squamous Cell Carcinoma In Situ A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of the underlying tissues. 8077/2 | morphology || Epidermoid carcinoma in situ, NOS | primary_diagnosis || Intraepidermal carcinoma, NOS | primary_diagnosis || Intraepithelial squamous cell carcinoma | primary_diagnosis || Squamous cell carcinoma in situ, NOS | primary_diagnosis || Squamous intraepithelial neoplasia, grade III | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C27425 High Grade Esophageal Intraepithelial Neoplasia Esophageal intraepithelial neoplasia characterized by architectural abnormalities and dysplasia involving both the lower and the upper half of the esophageal epithelium. It includes moderate dysplasia and carcinoma in situ (severe dysplasia). 8148/2 | morphology || Esophageal intraepithelial neoplasia, high grade | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C2899 Biliary Tract Disorder A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma. Biliary Disorder | comorbidities || Biliary Disorder | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C29019 Ketotrexate Disodium The sodium salt of ketotrexate, a synthetic antimetabolite analogue of folate with antineoplastic activity. Upon administration, ketotrexate competes for the folate binding site of the enzyme dihydrofolate reductase, resulting in inhibition of tetrahydrofolate synthesis, depletion of nucleotide pools, and inhibition of DNA, RNA and protein synthesis. (NCI04) Emofolin Sodium | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C29435 DNA Minor Groove Binding Agent SJG-136 A sequence-selective pyrrolobenzodiazepine (PBD) dimer with potential antineoplastic activity. Following intravenous administration, DNA minor groove binding agent SJG-136 preferentially and covalently binds to purine-GATC-pyrimidine sequences, with the imine/carbinolamine moieties of SJG-136 binding to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links and inhibits both DNA replication and gene transcription, which lead to the inhibition of cell growth. With a preference for binding to purine-GATC-pyrimidine sequences, SJG-136 adducts do not appear to be susceptible to p53-mediated DNA excision repair. DNA Minor Groove Binding Agent SG2000 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C3105 Von Hippel-Lindau Syndrome An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004 Von Hippel-Lindau Syndrome | comorbidities || Von Hippel-Lindau Syndrome | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C36184 Necrosis A finding indicating the presence of cellular necrosis in a tissue specimen. Necrosis | weiss_assessment_findings C104015 weiss_assessment_findings C C177537 GDC Value Terminology C40557 Metastatic Disease A finding indicating that a tumor has spread from its original site of growth to another anatomic site. Metastasis, NOS | metastasis_at_diagnosis || Metastatic | tumor_descriptor || Presented with Metastases | first_event || metastasis | classification_of_tumor C162221 || C166229 || C174459 || C198107 classification_of_tumor || first_event || metastasis_at_diagnosis || tumor_descriptor C C177537 GDC Value Terminology C4107 Lymphoepithelial Carcinoma A nonkeratinizing carcinoma which occurs predominantly in the nasopharynx but also in the tonsils and rarely in other anatomic sites. It is characterized by the presence of large malignant cells with vesicular nuclei, prominent nucleoli, syncytial growth pattern, and a lymphoplasmacytic infiltrate. 8082/3 | morphology || Lymphoepithelial carcinoma | primary_diagnosis || Lymphoepithelioma | primary_diagnosis || Lymphoepithelioma-like carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4116 Urothelial Carcinoma In Situ A neoplastic lesion in which the urothelium of the bladder, renal pelvis and/or ureter displays cells with malignant cytological characteristics and abnormal architectural features without evidence of stromal invasion. 8120/2 | morphology || Transitional cell carcinoma in situ | primary_diagnosis || Urothelial carcinoma in situ | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4127 Diffuse-Type Adenocarcinoma An adenocarcinoma characterized by the presence of a diffuse cellular infiltrate which is composed of poorly cohesive cells with minimal or no glandular formations. Representative example is the gastric diffuse adenocarcinoma. 8145/3 | morphology || Adenocarcinoma, diffuse type | primary_diagnosis || Carcinoma, diffuse type | primary_diagnosis || Poorly cohesive carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4150 Pituitary Gland Basophil Carcinoma A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with basic dyes. 8300/3 | morphology || Basophil adenocarcinoma | primary_diagnosis || Basophil carcinoma | primary_diagnosis || Mucoid cell adenocarcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4474 Skin Mixed Tumor A rare, benign, slow-growing, and painless neoplasm that arises from the sweat glands, usually in the head and neck region. It is characterized by the presence of epithelial, myoepithelial, and mesenchymal components. 8940/0 | morphology || Chondroid syringoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C45602 Bronchial Mixed Squamous and Glandular Papilloma An exceedingly rare benign endobronchial neoplasm characterized by the presence of fibrovascular cores lined by both squamous and glandular epithelium. Patients present with obstructive symptoms. Complete resection is curative. 8560/0 | morphology || Mixed squamous cell and glandular papilloma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4882 Myoma A mesenchymal neoplasm with benign histopathological features that arises from smooth, skeletal, or cardiac muscle cells. This category includes leiomyomas and rhabdomyomas. 8895/0 | morphology || Myoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C530 Therapeutic Growth Factor Formulated therapeutic proteins that are either isolated from endogenous sources or manufactured in a laboratory. Growth factors bind to specific receptors expressed by various cell types, thereby stimulating cell differentiation and/or proliferation. (NCI04) Growth factor | drug_category C188388 drug_category C C177537 GDC Value Terminology C65194 Gastric Adenocarcinoma with Parietal Cell Differentiation An adenocarcinoma of the stomach characterized by the presence of malignant epithelial cells that arise from, or differentiate towards parietal cells and exhibit eosinophilic, finely granular cytoplasm. 8214/3 | morphology || Parietal cell adenocarcinoma | primary_diagnosis || Parietal cell carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66807 Benign Ciliary Body Medulloepithelioma A rare benign embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium. 9501/0 | morphology || Medulloepithelioma, benign | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66809 Benign Ciliary Body Teratoid Medulloepithelioma A rare benign embryonal neoplasm typically presenting as a ciliary body mass during childhood. It arises from primitive medullary epithelium and contains heterologous elements, particularly cartilage, skeletal muscle, and brain tissue. 9502/0 | morphology || Teratoid medulloepithelioma, benign | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C7009 Germinoma A malignant germ cell tumor arising from the central nervous system. It is composed of uniform cells resembling primitive germ cells. These cells have large, vesicular nuclei, prominent nucleoli and a clear, glycogen-rich cytoplasm. Additional features are lymphoid or lymphoplasmacytic infiltrates and, less frequently, scattered syncytiotrophoblastic giant cells. (Adapted from WHO) 9064/3 | morphology || Germinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C7017 Sellar Region Granular Cell Tumor A generally benign intrasellar and/or suprasellar mass arising from the neurohypophysis or infundibulum. It is composed of nests of large cells with granular, eosinophilic cytoplasm due to abundant intracytoplasmic lysosomes. It generally has a slow progression and lacks invasive growth. (Adapted from WHO) 9582/0 | morphology || Granular cell tumor of the sellar region | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C71524 Epofolate A folate receptor-targeting antimitotic agent with potential antineoplastic activity. Epofolate contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation. Folate Receptor Targeted Epothilone BMS753493 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C78199 FAK Inhibitor PF-00562271 Besylate The besylate salt form of PF-00562271, an orally bioavailable small molecule and ATP-competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities. FAK inhibitor PF-00562271 inhibits the tyrosine kinase FAK, and to a lesser extent, proline-rich tyrosine kinase (PYK2), which may inhibit tumor cell migration, proliferation, and survival. As FAK is a signal transducer for integrins, inhibition of FAK by this agent may prevent integrin-mediated activation of several downstream signals including ERK, JNK/MAPK and PI3K/Akt. FAK and PYK2, upregulated in many tumor cell types, are involved in tumor cell invasion, migration and proliferation. FAK Inhibitor PF-00562271 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C7855 Stage 0 Vaginal Cancer AJCC v6 and v7 Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.) 8077/2 | morphology C176985 morphology C C177537 GDC Value Terminology C8106 Dysgerminoma A malignant germ cell tumor arising from the ovary. Morphologically, it is identical to seminoma and consists of a monotonous population of germ cells with abundant pale cytoplasm and uniform nuclei. The stroma invariably contains chronic inflammatory cells, mostly T-lymphocytes. It responds to chemotherapy or radiotherapy and the prognosis relates to the tumor stage. 9060/3 | morphology || Dysgerminoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C84444 Metabolic Dysfunction-Associated Steatotic Liver Disease Fatty replacement of the hepatic parenchyma not related to alcohol use. Causes include obesity and diabetes. Nonalcoholic Fatty Liver Disease | comorbidities || Nonalcoholic Fatty Liver Disease | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C84445 Metabolic Dysfunction-Associated Steatohepatitis Fatty replacement of the hepatic parenchyma with damage to the hepatocytes not related to alcohol use. It may lead to cirrhosis and liver failure. Nonalcoholic Steatohepatitis | comorbidities || Nonalcoholic Steatohepatitis | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C84855 Anti-CD70 Antibody-Ddrug Conjugate MDX-1203 An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody, directed against the extracellular domain of the human CD70 molecule, conjugated to a prodrug of a CC-1065 (rachelmycin) analogue via a stable peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate MDX-1203 selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the prodrug moiety is released and activated and binds to double-stranded B-DNA within the minor groove, thereby alkylating the -3 position of adenine, which may result in the inhibition of cellular proliferation of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The antitumor antibiotic CC-1065, a DNA minor-groove-binding alkylating agent, was originally isolated from the bacterium Streptomyces zelensis. Anti-CD70 Antibody-Drug Conjugate MDX-1203 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C89476 Vaginal Intraepithelial Neoplasia 3 Vaginal intraepithelial neoplasia characterized by the presence of intraepithelial neoplastic changes that involve the entire thickness of the epithelium. VAIN III | primary_diagnosis || Vaginal intraepithelial neoplasia, grade III | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C916 Ubidecarenone A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04) Coenzyme Q10 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C92590 Anti-AGS-5 Antibody-drug Conjugate ASG-5ME An antibody drug conjugate (ADC) containing the fully human IgG2k monoclonal antibody targeting an epitope of SLC44A4 (AGS-5) linked, via a valine-citrulline (vc) maleimidocaproyl (mc) linker, to the antimicrotubulin drug monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of ASG-5ME selectively binds to AGS-5. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. SLC44A4, potentially a sodium-dependent transmembrane transport protein, is overexpressed on more than 80 percent of samples derived from patients with pancreatic, prostate and gastric cancers. Anti-AGS-5 Antibody-Drug Conjugate ASG-5ME | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C9288 Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate. 9896/3 | morphology || Acute myeloid leukaemia, t(8;21)(q22;q22) | primary_diagnosis || Acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 | primary_diagnosis || Acute myeloid leukemia, AML1(CBF-alpha)/ETO | primary_diagnosis || FAB M2, AML1(CBF-alpha)/ETO | primary_diagnosis || FAB M2, t(8;21)(q22;q22) | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C93207 DNA Microarray Analysis This term describes an experiment in which probes representing genes that one wants to study are affixed to a substrate (e.g., a glass slide) and then exposed to target molecules (sometimes referred to as the sample). The level of hybridization between a specific probe and a target (typically indicated through fluorescence and measured through image analysis) indicates the level of the gene corresponding to that probe in a test solution. Expression Array | experimental_strategy C43622 experimental_strategy C C177537 GDC Value Terminology C95963 Ampulla of Vater Pancreaticobiliary/Gastric Type Adenocarcinoma An invasive adenocarcinoma that arises from the ampulla of Vater and is characterized by the presence of malignant cells that resemble pancreatic ductal or extrahepatic bile duct carcinoma malignant cells, or malignant cells with gastric-like mucin. 8163/3 | morphology || Pancreatobiliary-type carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C96807 Bile Duct Intraductal Papillary Neoplasm with Low Grade Intraepithelial Neoplasia An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts and is characterized by the presence of mild epithelial atypia. 8503/0 | morphology || Intraductal papillary neoplasm with low grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C96809 Bile Duct Intraductal Papillary Neoplasm with High Grade Intraepithelial Neoplasia An intraductal papillary neoplasm that arises from the epithelium of the intrahepatic or extrahepatic bile ducts and is characterized by the presence of severe epithelial atypia. 8503/2 | morphology || Intraductal papillary neoplasm with high grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C96877 Intracholecystic Papillary Neoplasm, Low Grade An intracholecystic papillary neoplasm that arises from the epithelium of the gallbladder and is characterized by the presence of mild epithelial dysplasia. 8503/0 | morphology || Intracystic papillary neoplasm with low grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C97503 Acinterferon Alfa A proprietary recombinant protein highly resembling human interferon alpha 2b (IFN-a2b), with potential anti-tumor, anti-inflammatory, immunomodulating and antiviral activities. Upon injection, acinterferon alfa binds to specific IFN alpha cell surface receptors. This activates interferon-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-specific response elements (ISREs). This may activate the immune system, including the activation of natural killer cells (NKs) and may result in an inhibition of tumor cell proliferation, tumor angiogenesis, metastasis and an induction of apoptosis. Compared to human IFN-a2b (HuINF-a2b), this agent exhibits enhanced antiviral and antiproliferative activities. In addition, this agent exhibits antiviral activity against a variety of viruses, including hepatitis B and C viruses, human immunodeficiency virus (HIV) and Avian Influenza. Recombinant Interferon Alpha 2b-like Protein | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C113790 PH20 Hyaluronidase-expressing Adenovirus VCN-01 An oncolytic, replication-competent adenovirus encoding the human glycosylphosphatidylinositol-anchored enzyme PH20 hyaluronidase with potential antitumor activity. After intratumoral administration, PH20 hyaluronidase-expressing adenovirus VCN-01 selectively replicates in tumor cells, which may both cause oncolytic virus-induced cell death and induce the infection of adjacent tumor cells. In addition, the virus expresses hyaluronidase, which hydrolyzes and degrades the hyaluronic acid (HA) that coats tumor cells. The degradation of HA may result in a decrease for both the viscosity of the interstitial space and the tumor's interstitial fluid pressure (IFP). This increases viral spread and may result in the inhibition of tumor cell growth. In addition, HA degradation facilitates the penetration of chemotherapeutic agents into the tumor. HA is a glycosaminoglycan found in the extracellular matrix (ECM) and is frequently overproduced by various tumor cell types. The presence of HA in tumors correlates with increases in tumor cell growth, metastatic potential, tumor progression and resistance to chemotherapeutic agents. PH20 Hyaluronidase-expressing Adenovirus VCN-01 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C126648 ALK/FAK/Pyk2 Inhibitor CT-707 An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, ALK/FAK/Pyk2 inhibitor CT-707 selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis. ALK/FAK/Pyk2 Inhibitor CT-707 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C141074 ERK1/2 Inhibitor KO-947 An inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon intravenous administration, KO-947 specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells. ERK1/2 Inhibitor KO-947 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C14161 Low Grade Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive. Low Grade | tumor_grade C28076 tumor_grade D C177537 GDC Value Terminology C14167 Poorly Differentiated Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread. Poorly Differentiated | additional_pathology_findings C158809 additional_pathology_findings D C177537 GDC Value Terminology C14171 Well Differentiated Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells. Well Differentiated | additional_pathology_findings C158809 additional_pathology_findings D C177537 GDC Value Terminology C142777 Wnt Signaling Pathway Inhibitor SM08502 An orally bioavailable, small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, SM08502 inhibits the expression of genes involved in the Wnt signaling pathway through an as of yet not fully elucidated mechanism. This decreased expression of Wnt pathway-related genes prevents Wnt signaling and may inhibit proliferation of cancer cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is dysregulated in many cancer cell types and plays a crucial role in tumor cell proliferation. Wnt Signaling Pathway Inhibitor SM08502 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C161831 Autologous PRAME-targeting TCR-engineered T-cells IMA203 A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous PRAME-targeting TCR-engineered T-cells IMA203 specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types. Autologous TCR-engineered T-cells IMA203 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C165656 Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-BCMA/anti-CD3 bispecific antibody REGN5459 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Anti-BCMA/Anti-CD3 Bispecific Antibody REGN5459 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C165696 Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22 A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CD22 with potential immunomodulating and antineoplastic activities. Upon transfusion, allogeneic CD22-specific universal CAR-expressing T-lymphocytes UCART22 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells. Allogeneic CD22-specific Universal CAR-expressing T-lymphocytes UCART22 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C170765 c-Met Inhibitor ABN401 An orally bioavailable, highly selective inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, ABN401 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. c-Met Inhibitor ABN401 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C173153 Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130 A preparation of human allogeneic T-lymphocytes gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to disrupt expression of endogenous TCR and major histocompatibility complex (MHC) class I molecules and modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human cluster of differentiation 70 (CD70), with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD70 CAR T-cells CTX130 recognize and bind to CD70-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD70-positive tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. Disruption of endogenous TCR prevents graft-versus-host disease (GvHD); the disruption of MHC class I molecules increases the persistence of the CAR T-cells. Allogeneic CRISPR-Cas9 Engineered Anti-CD70 CAR-T Cells CTX130 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C26676 Transferrin-CRM107 A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. (NCI04) Transferrin-CRM107 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C27261 Pre T-ALL 9837/3 | morphology || Pre-T ALL | primary_diagnosis || Pro-T ALL | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C27797 Common Acute Lymphoblastic Leukemia 9836/3 | morphology || Common ALL | primary_diagnosis || Common precursor B ALL | primary_diagnosis || c-ALL | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C27814 Bile Duct Carcinoma A carcinoma arising from the intrahepatic or extrahepatic bile ducts. 8160/3 | morphology || Bile Duct Cancer | relationship_primary_diagnosis || Bile duct carcinoma | primary_diagnosis C176985 || C177621 || C178243 morphology || primary_diagnosis || relationship_primary_diagnosis D C177537 GDC Value Terminology C27820 Mature T-ALL 9837/3 | morphology || Cortical T ALL | primary_diagnosis || Mature T ALL | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C28083 Intermediate Grade A term referring to the degree of differentiation of a malignant neoplasm and indicating that it is moderately differentiated. Intermediate Grade | tumor_grade C28076 tumor_grade D C177537 GDC Value Terminology C3157 Leiomyoma A well-circumscribed benign smooth muscle neoplasm characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. 8890/0 | morphology || Leiomyoma | additional_pathology_findings || Leiomyoma, NOS | primary_diagnosis C158809 || C176985 || C177621 additional_pathology_findings || morphology || primary_diagnosis D C177537 GDC Value Terminology C34774 Chronic Monocytic Leukemia 9860/3 | morphology || Chronic monocytic leukemia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C35725 Grade II Neuroendocrine Carcinoma 8249/3 | morphology || Neuroendocrine carcinoma, moderately differentiated | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C35727 Grade I Neuroendocrine Carcinoma 8240/3 | morphology || Neuroendocrine carcinoma, low grade | primary_diagnosis || Neuroendocrine carcinoma, well-differentiated | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C3844 Gallbladder Carcinoma A malignant tumor arising from the epithelium of the gallbladder. It is usually associated with the presence of gallstones. Clinical symptoms are not specific and usually present late in the course. Morphologically, most gallbladder carcinomas are adenocarcinomas; squamous cell carcinomas, adenosquamous carcinomas, signet ring carcinomas, and undifferentiated carcinomas can also occur. Gallbladder Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis D C177537 GDC Value Terminology C4000 Stage 0 Cervical Cancer AJCC v6 Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.) 8077/2 | morphology || CIN III with severe dysplasia | primary_diagnosis || Cervical intraepithelial neoplasia, grade III | primary_diagnosis || Cin III, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C4063 Myomatous Neoplasm A benign or malignant mesenchymal neoplasm arising from smooth, skeletal, or cardiac muscle. Myomatous Neoplasms | disease_type C2991 disease_type D C177537 GDC Value Terminology C4115 Transitional Cell Papilloma A benign papillary neoplasm composed of transitional cells which show preservation of the nuclear polarity. 8120/1 | morphology || Transitional cell papilloma, NOS | primary_diagnosis || Transitional cell papilloma, benign | primary_diagnosis || Transitional papilloma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C4118 Inverted Transitional Cell Papilloma A benign papillary neoplasm composed of transitional cells and characterized by an endophytic growth pattern. 8121/0 | morphology || 8121/1 | morphology || Transitional cell papilloma, inverted, NOS | primary_diagnosis || Transitional cell papilloma, inverted, benign | primary_diagnosis || Transitional papilloma, inverted, NOS | primary_diagnosis || Transitional papilloma, inverted, benign | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C4883 Malignant Muscle Neoplasm A malignant neoplasm affecting the skeletal or smooth muscles. Malignant neoplasms arising from the skeletal muscles are called rhabdomyosarcomas. Malignant neoplasms arising from the smooth muscles are called leiomyosarcomas. 8895/3 | morphology || Myosarcoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C54317 Odontoameloblastoma A rare, locally aggressive neoplasm arising from tooth-forming tissues. It occurs in the mandible and maxilla. It is characterized by the presence of odontogenic epithelium and adjacent myxoid tissue, fibrous stroma, and mineralized dental tissues. 9311/0 | morphology || Odontoameloblastoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C66751 Granulosa Cell-Theca Cell Tumor A general term used to describe sex cord-stromal tumors characterized by the presence of granulosa cells in a thecomatous/fibrothecomatous background. 8621/1 | morphology || Granulosa cell-theca cell tumor | primary_diagnosis || Theca cell-granulosa cell tumor | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C66752 Clear Cell Neoplasm A purely morphologic term that describes a neoplasm in which all or the majority of the neoplastic cells have a clear cytoplasm, when examined under light microscopy, using the conventional staining method (H-E). This term does not provide any information about the nature of the neoplasm (benign or malignant), cell of origin (e.g. epithelial versus mesenchymal versus hematopoietic), or prognosis. Further examination using special stains and/or immunohistochemistry is required to appropriately classify this tumor. 8005/0 | morphology || Clear cell tumor, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C66803 Cerebellar Sarcoma An obsolete term referring to desmoplastic medulloblastoma. 9480/3 | morphology || Cerebellar sarcoma, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C66816 Spontaneously Regressed Retinoblastoma An archaic term that refers to benign, non-progressive retinal lesions in patients with mutation of the RB1 gene. 9514/1 | morphology || Retinoblastoma, spontaneously regressed | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C7159 Subepidermal Nodular Fibrosis 8832/0 | morphology || Subepidermal nodular fibrosis | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C7364 Diffuse Intraductal Papillomatosis Diffuse intraductal papillomatosis | primary_diagnosis C177621 primary_diagnosis D C177537 GDC Value Terminology C7380 Thyroid Gland Papillary and Follicular Carcinoma 8340/3 | morphology || Papillary and follicular adenocarcinoma | primary_diagnosis || Papillary and follicular carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C7927 Liver Carcinoma A carcinoma that arises from the hepatocytes or intrahepatic bile ducts. The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma. Liver Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis D C177537 GDC Value Terminology C8975 Female Reproductive System Carcinosarcoma An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women. The endometrium and ovary are the most common sites of tumor origin. Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements. 8981/3 | morphology || Carcinosarcoma, embryonal | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C8994 Malignant Lymphoma Centroblastic, Follicular An antiquated term that refers to a follicular non-Hodgkin lymphoma composed predominantly of large B-lymphocytes. 9698/3 | morphology || Malignant lymphoma, centroblastic, follicular | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C95493 Pancreatic Mucinous-Cystic Neoplasm, High Grade A non-invasive mucinous cystic neoplasm that arises from the exocrine pancreas and is characterized by the presence of severe dysplasia. The neoplastic columnar mucin-producing epithelial cells form papillae with irregular branching and budding. There is nuclear stratification, prominent nucleoli, and cellular pleomorphism. Mitotic activity is present and the mitoses may be atypical. 8470/2 | morphology || Mucinous cystic neoplasm with high-grade dysplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C95506 Pancreatic Intraductal Tubulopapillary Neoplasm An epithelial neoplasm that arises from the exocrine pancreas characterized by the formation of tubular structures, high grade dysplasia, and ductal differentiation. Grossly, it is characterized by the presence of intraductal nodular masses. Morphologically, there are nodules of tubular glands and occasional papillary structures growing in dilated ducts. There is no significant mucin production. Signs and symptoms include epigastric pain, weight loss, vomiting, steatorrhea, and diabetes mellitus. Intraductal tubulopapillary neoplasm | primary_diagnosis C177621 primary_diagnosis D C177537 GDC Value Terminology C95514 Pancreatic Intraductal Papillary Mucinous Neoplasm, Oncocytic-Type A pancreatic intraductal papillary mucinous neoplasm characterized by the presence of neoplastic epithelial cells with abundant eosinophilic granular cytoplasm. 8453/0 | morphology || Intraductal papillary-mucinous adenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C95913 Ampullary Noninvasive Papillary Neoplasm, Pancreatobiliary Type An exophytic, preinvasive, papillary epithelial neoplasm that arises from the ampulla of Vater. Histologically it resembles the papillary neoplasms of the biliary tree. This category includes neoplasms with low grade dysplasia and high grade dysplasia. 8163/0 | morphology || Pancreatobiliary neoplasm, non-invasive | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C95914 Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with Low Grade Dysplasia An ampullary noninvasive papillary neoplasm of the pancreatobiliary type characterized by the presence of low grade dysplasia. 8163/0 | morphology || Noninvasive pancreatobiliary papillary neoplasm with low grade dysplasia | primary_diagnosis || Noninvasive pancreatobiliary papillary neoplasm with low grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C95915 Ampullary Noninvasive Pancreatobiliary Papillary Neoplasm with High Grade Dysplasia An ampullary noninvasive papillary neoplasm of the pancreatobiliary type characterized by the presence of high grade dysplasia. 8163/2 | morphology || Noninvasive pancreatobiliary papillary neoplasm with high grade dysplasia | primary_diagnosis || Noninvasive pancreatobiliary papillary neoplasm with high grade intraepithelial neoplasia | primary_diagnosis || Papillary neoplasm, pancreatobiliary-type, with high grade intraepithelial neoplasia | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis